Fosamax Cost in West Virginia 2026: Prices, Medicaid, and Your Cheapest Options

What Alendronate Actually Does

Alendronate is a bisphosphonate that slows the activity of osteoclasts, the cells that break down bone. By reducing bone resorption, it increases bone mineral density (BMD) and cuts fracture risk in postmenopausal women and men with osteoporosis.

The evidence base here is large. The Fracture Intervention Trial (FIT, N=2,027, published in JAMA 1998) showed that alendronate reduced the risk of hip fracture by 51% and vertebral fracture by 47% over three years compared with placebo in postmenopausal women with low femoral neck BMD. [1] That trial remains one of the most-cited bisphosphonate studies in clinical practice guidelines today.

The FDA approved alendronate in 1995 under the brand name Fosamax. [2] Generic versions became widely available after patent expiration, which is the primary reason cash prices in states like West Virginia are now dramatically lower than the original list price.

The standard adult dose for osteoporosis treatment is 70 mg once weekly, taken with plain water 30 minutes before the first food, beverage, or medication of the day. Patients must remain upright for at least 30 minutes after swallowing the tablet to reduce esophageal irritation risk. A 10 mg once-daily formulation exists but is rarely used because the weekly 70 mg tablet offers the same efficacy with simpler adherence.

Alendronate also carries FDA approval for osteoporosis prevention in postmenopausal women at a lower 35 mg once-weekly dose and for treatment of glucocorticoid-induced osteoporosis at 5 mg or 10 mg daily. [2]

What Fosamax and Generic Alendronate Actually Cost in West Virginia in 2026

Generic alendronate 70 mg weekly tablets cost approximately $15 per month at West Virginia retail pharmacies when purchased with a discount card. Brand Fosamax carries a Merck list price near $80 per month, but almost no cash-paying patient needs to pay that amount.

West Virginia pharmacies statewide, including chains like CVS, Walgreens, Kroger, and Walmart, participate in GoodRx and similar discount networks. A 4-tablet supply of generic alendronate 70 mg (one month) through GoodRx typically falls between $9 and $18 depending on the specific pharmacy and its contract pricing.

Here is a working price breakdown for WV residents in 2026:

| Purchase Method | Estimated Monthly Cost | |---|---| | Brand Fosamax, no insurance | ~$80 | | Generic alendronate, no coupon | ~$25-$35 | | Generic alendronate with GoodRx | ~$9-$18 | | Generic alendronate with insurance (commercial) | $0-$15 (tier 1-2 copay) | | Compounded alendronate (503A, patient assistance) | $0 |

The gap between the $80 brand price and the $15 generic cash price exists because multiple manufacturers now produce alendronate sodium tablets, and competition has driven margins very low. Patients who present a Merck Fosamax savings card at a retail pharmacy may reduce brand costs, but switching to the generic is almost always the faster route to savings for uninsured West Virginians.

Does West Virginia Medicaid Cover Fosamax?

West Virginia Medicaid does not cover brand Fosamax as of 2026. Generic alendronate's formulary status within WV Medicaid managed-care plans varies by plan, and patients should confirm coverage directly with their specific plan.

This is a meaningful gap. West Virginia has one of the highest rates of osteoporosis-related hospitalizations in the country. The CDC's Behavioral Risk Factor Surveillance System data show that West Virginia adults report some of the nation's highest rates of arthritis and musculoskeletal disease burden. [3] Untreated osteoporosis in a state with high fall risk and limited rural specialist access carries serious downstream costs.

If a WV Medicaid managed-care plan denies alendronate, the enrollee has two practical options. First, the prescriber can submit a prior authorization or exception request citing the patient's T-score and fracture risk. Second, the patient can purchase generic alendronate at retail cash price using a discount card since the monthly cost of $9 to $18 may be affordable even on Medicaid income levels.

Patients enrolled in Medicare Part D should check their plan's formulary directly. Most Part D plans place generic alendronate on Tier 1 or Tier 2, meaning copays of $0 to $15 per month are common.

Which Private Insurance Plans Cover Fosamax in West Virginia?

Most commercial insurance plans sold through the West Virginia ACA marketplace and employer-sponsored plans cover generic alendronate. Brand Fosamax coverage is less consistent because the generic is therapeutically equivalent and dramatically cheaper.

The major carriers operating in West Virginia include Highmark Blue Cross Blue Shield of West Virginia, The Health Plan (based in Wheeling), and several national plans through the federal exchange. Generic alendronate typically sits at Tier 1 or Tier 2 on these formularies, producing copays of $0 to $15 per 30-day supply for patients who have met their deductible.

Before your deductible is met, you pay the plan's contracted rate for the drug, which is usually close to the GoodRx cash price anyway. In those cases, asking your pharmacist to run a GoodRx coupon instead of billing insurance can save you money if you have a high-deductible plan.

The American Society for Bone and Mineral Research and the Endocrine Society both recommend confirming patient adherence at each visit, partly because cost barriers are a documented driver of bisphosphonate discontinuation. A 2022 review published via the National Institutes of Health found that cost-related nonadherence affects up to 30% of patients prescribed osteoporosis medications. [4]

Is Compounded Alendronate Legal in West Virginia?

Yes, compounded alendronate is legally available through licensed 503A compounding pharmacies operating in West Virginia. These pharmacies operate under state pharmacy board oversight and must compound prescriptions for specific patients pursuant to a valid prescription from a licensed prescriber.

The legal framework matters here. 503A pharmacies in the U.S. are regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act and by state boards of pharmacy. West Virginia's Board of Pharmacy follows the USP <795> and <797> guidelines for non-sterile and sterile preparations respectively. Alendronate compounding for oral administration falls under USP <795> as a non-sterile preparation.

Why would a patient choose compounded alendronate over the $15-per-month generic? A few reasons are clinically relevant. Some patients have documented esophageal conditions that make the standard oral tablet problematic, and a compounded oral solution or alternate formulation may be prescribed. Other patients qualify for compounding pharmacy patient-assistance programs that bring the cost to $0 per month, which is below even the $9 GoodRx floor for the generic tablet.

Prescribers considering compounded alendronate should note that FDA does not review compounded drug products for safety or efficacy, and the bioavailability of a compounded preparation may differ from the FDA-approved tablet. That distinction should be part of the informed-consent discussion.

The HealthRX clinical team applies a three-step cost-access framework for WV patients prescribed alendronate:

1. Start with GoodRx or a similar discount card at the nearest retail pharmacy. For most WV patients, this brings monthly cost to under $18 with no paperwork.
2. If cost remains a barrier or insurance coverage is denied, request a prior authorization using the patient's DXA T-score and FRAX fracture risk score as supporting documentation.
3. If steps one and two fail, refer to a licensed 503A compounding pharmacy in West Virginia with an active patient-assistance program. Confirm the pharmacy's board registration before prescribing.

How to Get a Fosamax Prescription via Telehealth in West Virginia

Telehealth prescribing of alendronate is permitted in West Virginia. A licensed prescriber, whether a physician, nurse practitioner, or physician assistant, can evaluate osteoporosis risk factors remotely and issue an alendronate prescription that is filled at any in-state or mail-order pharmacy.

West Virginia's telehealth laws allow synchronous audio-video visits and, in some circumstances, telephone-only visits for established patients. The prescriber must hold a valid West Virginia license or operate under a valid interstate compact agreement.

The practical workflow for a telehealth alendronate prescription typically runs as follows. The patient uploads recent DXA scan results, a list of current medications, and relevant lab work (calcium, vitamin D, creatinine) before the visit. The prescriber reviews fracture risk using the FRAX calculator, confirms no contraindications such as creatinine clearance <35 mL/min, severe hypocalcemia, or inability to sit upright for 30 minutes, and then sends the prescription electronically to the patient's chosen pharmacy.

HealthRX providers follow Endocrine Society guidelines, which state: "Pharmacological therapy is recommended for postmenopausal women with osteoporosis (T-score ≤-2.5 at the lumbar spine, femoral neck, or total hip) or for those with a prior fragility fracture." [5] That threshold applies equally whether the visit is in-person or telehealth.

Discount Programs and Savings Cards Available to West Virginia Residents

Several savings options exist for West Virginians paying out of pocket for alendronate.

GoodRx is the most widely used. Free to sign up, it provides a discount code accepted at virtually all West Virginia retail pharmacies. Presenting the GoodRx code at Walmart Pharmacy in Charleston, CVS in Morgantown, or any independent pharmacy in Beckley or Huntington typically yields a price between $9 and $18 per month for generic alendronate 70 mg.

Merck's savings program for brand Fosamax exists but applies primarily to commercially insured patients and has income eligibility limits. Given that the generic is roughly $60 cheaper per month, most prescribers direct patients immediately to the generic.

NeedyMeds and RxAssist maintain databases of manufacturer patient-assistance programs. Patients with household incomes below 200% to 400% of the federal poverty level may qualify for free or near-free branded bisphosphonate products through these programs, though alendronate's low generic price makes other bisphosphonates (such as zoledronic acid infusions) more likely candidates for assistance programs.

The West Virginia Bureau for Medical Services also administers the CHIP (Children's Health Insurance Program) program for eligible minors, though alendronate is rarely prescribed in pediatric populations outside of rare metabolic bone diseases.

One option West Virginia patients frequently miss: asking the prescribing office directly whether free samples or a 90-day supply through mail-order pharmacy is available. A 90-day supply of generic alendronate through mail-order often costs $20 to $40 total, lowering the effective monthly cost to under $14.

Clinical Efficacy: Why Alendronate Remains First-Line

Alendronate's evidence record explains why it remains the most commonly prescribed oral bisphosphonate despite being off-patent for decades.

The FIT trial demonstrated a 47% relative risk reduction in morphometric vertebral fractures and a 51% reduction in hip fractures over 36 months of treatment. [1] These numbers come from a randomized, placebo-controlled trial with over 2,000 participants and hard fracture endpoints, not surrogate BMD measures alone.

A 2011 Cochrane meta-analysis of alendronate for primary and secondary prevention of osteoporotic fractures (pooling data from 11 trials, N=12,855) confirmed a 45% relative risk reduction in vertebral fractures and a 16% reduction in non-vertebral fractures. [6] The effect on hip fracture specifically reached 40% relative risk reduction in high-risk populations.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women lists alendronate as a first-line agent alongside risedronate and zoledronic acid. [5] The American Association of Clinical Endocrinology (AACE) 2020 guidelines similarly place alendronate in the first-line category for most postmenopausal women with osteoporosis who lack contraindications. [7]

Contraindications relevant to WV prescribers include estimated glomerular filtration rate (eGFR) below 30 to 35 mL/min/1.73m², which is relevant given West Virginia's high rates of chronic kidney disease, abnormalities of the esophagus, hypocalcemia, and inability to stand or sit upright for 30 minutes.

Drug holidays, typically considered after five to seven years of continuous oral bisphosphonate therapy, are an active clinical discussion. The FLEX trial showed that patients who stopped alendronate after five years maintained significant fracture protection for a further five years compared with those who never received treatment, though morphometric vertebral fracture risk rose modestly versus continuing therapy. [8] Prescribers should reassess fracture risk at the five-year mark for every patient.

Monitoring Alendronate Therapy in West Virginia

Baseline labs before starting alendronate should include serum calcium, 25-hydroxyvitamin D, and a basic metabolic panel including creatinine. Vitamin D deficiency is particularly prevalent in West Virginia, with NHANES survey data showing approximately 35% of adults in Appalachian states having serum 25-OH vitamin D below 20 ng/mL. [9] Correcting vitamin D deficiency before starting alendronate reduces the risk of hypocalcemia and improves treatment response.

DXA scanning at baseline and after two years of therapy is standard. Most commercial insurers and Medicare Part B cover DXA scans every two years for patients with documented osteoporosis. West Virginia has a limited number of DXA scanners relative to its geographic size, so telehealth prescribers should confirm whether the patient has access to a local facility or needs a referral to a regional center.

Rare but serious adverse effects of long-term alendronate use include atypical femoral fractures (AFFs) and osteonecrosis of the jaw (ONJ). The American Society for Bone and Mineral Research task force estimates AFF incidence at 3.2 to 50 cases per 100,000 person-years of bisphosphonate use, with risk rising after five years. [10] Patients should be counseled to report new thigh or groin pain. Dental work should be completed before starting therapy when possible, and patients should inform their dentist of bisphosphonate use.